Testing whether adrenomedullin can trigger migraine attacks in people with migraine without aura
Tests if adrenomedullin triggers migraine attacks in adults with migraine without aura.
Plain-language title generated from the registry record
Registry title: Selective Activation of the Adrenomedullin Receptors in Migraine
Key facts
- Where
- Glostrup Municipality, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07451769, who can take part
Where in Denmark
- Danish Headache CenterGlostrup Municipality, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Danish Headache Center
- Trial code
- NCT07451769
- Record updated
- 28 August 2026
- Original description
Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.Read full original descriptionShow less
Selective Activation of the Adrenomedullin Receptors in Migraine: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.
Inclusion: Written informed consent has been obtained prior to the initiation of any study-specific procedures; Age ≥18 years at the time of screening; History of migraine without aura for at least 12 months prior to screening, with a frequency of 1-5 migraine attacks per month, based on medical records and/or patient self-report, and diagnosed in accordance with the ICHD-3 criteria.
Exclusion: History of any secondary headache disorder, per ICHD-3 criteria, prior to screening; Use of prophylactic migraine medication within 30 days or within 5 plasma half-lives (whichever is longer) prior to screening; Previous use of any therapies targeting the CGRP signaling pathway, including anti-CGRP ligand monoclonal antibodies, anti-CGRP receptor monoclonal antibodies, or small molecule CGRP receptor antagonists; History of any other primary headache disorder, except for tension-type headache with <5 headache days per month, based on ICHD-3 classification; Known risk of self-harm or harm to others, including a history of suicidal behavior; Any clinically significant disorder, condition, or disease (other than those permitted in the protocol) that, in the opinion of the investigator, could compromise participant safety or interfere with study procedures or data integrity; Positive urine pregnancy test at screening or on Day 1 in female participants of childbearing potential; Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study period; Evidence of current pregnancy or breastfeeding based on self-report or medical records; Inability or unwillingness to complete all protocol-required visits and procedures, or concerns regarding protocol adherence, as judged by the investigator.